Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Indiana University
UNC Lineberger Comprehensive Cancer Center
Heinrich-Heine University, Duesseldorf
N.N. Petrov National Medical Research Center of Oncology
Institut Claudius Regaud
Gustave Roussy, Cancer Campus, Grand Paris
Indiana University
Alliance for Clinical Trials in Oncology
Novartis
Hoosier Cancer Research Network
Centre Francois Baclesse
Indiana University
Gustave Roussy, Cancer Campus, Grand Paris